DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Roxadustat
Roxadustat
Roxadustat for the Treatment of Anemia Due to Chronic Kidney
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
Final Evidence Report
Nonclinical Characterization of the HIF-Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment for Anemia of Chronic Kidney
Roxadustat for the Treatment of Anemia in Patients with Chronic Kidney Diseases: a Meta-Analysis
Pretreatment with Roxadustat (FG-4592) Attenuates Folic Acid-Induced Kidney Injury Through Antiferroptosis Via Akt/GSK-3Β/Nrf2 Pathway
Prof. Andrzej Wiecek
Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease S
Anatomical Classification Guidelines V2021 EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021
New Anemia Treatments for Patients with Chronic Kidney Disease
Anemia of Chronic Diseases: Wider Diagnostics—Better Treatment?
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients
How I Treat Cancer Anemia
HIF Stabilization by Prolyl Hydroxylase Inhibitors for the Treatment of Anemia in Chronic Kidney Disease Christina M
Rxoutlook® 3Rd Quarter 2020
Highlights in Myelodysplastic Syndromes KYMRIAHCART T
Study Protocol Drug Substance Roxadustat Study Code D5740C00002 Version 8.0 Date 19 September 2018
Data Sheet of Clinical Trial C.T
Top View
Iron Deficiency in Chronic Kidney Disease
Mannose Binding Lectin Is Hydroxylated by Collagen Prolyl-4-Hydroxylase
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2018
FDA Briefing Document Cardiovascular and Renal Drugs
Recent Advances in Doping Analysis (28)
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
HIF-Α Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: a Comprehensive Review
Investor Presentation 9 March 2021 Tim Watts, CEO Brian Groch, CCO Disclaimer
Triferic® Dialysate and Triferic® AVNU, Develop FPC for New Indications, and Maintain Concentrate Sales
ROXADUSTAT) FIBROGEN* Phase II Studies Completed (ND CKD, HD, PD) Phase III Studies Ongoing (ND CKD, HD, PD)
Rxoutlook® 2Nd Quarter 2021
WALLET CARD2021 Examples of Prohibited and Permitted Substances and Methods Effective Jan
Statistical Analysis Plan Study Code D5740C00001 Edition Number 3.0 Date 28 September 2018
Fibrogen Roxadustat [Fg-4592]
Update on Randomized Clinical Trials in Anemia of CKD KDIGO Chuan-Ming Hao Division of Nephrology, Huashan Hospital Fudan University DISCLOSURES
Iron Therapy in Chronic Kidney Disease: Days of Future Past
Assessment Report
Roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients
Epoetin Alfa (N=1716)
Prolyl Hydroxylase Domain Inhibitors: a New Era in the Management of Renal Anemia
Controversias Sobre El Óptimo Manejo De La Anemia (2021) Descargar Pdf
Transcript-263-Iron-Def-Anemia-In-CKD
Klasifikacija ATC 2021
Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia
January 2018 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
Scientists Study New Ways to Slow Diabetic Kidney Disease Progression
Oral Iron Therapies in Development for Iron Deficiency in Chronic Kidney Disease
KDIGO Executive Conclusions
Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and Β-Thalassemia
Roxadustat (FG-4592; ASP1517; AZD9941)
Whether Prolyl Hydroxylase Blocker—Roxadustat—In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?
Article Efficacy and Safety of Daprodustat Compared
Review Anemia of Chronic Kidney Disease
1 SUMMARY Amgen Appreciates the Opportunity to Comment on ICER's
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience
United States Securities and Exchange Commission Form